April 28, 2010 – About 280,000 external defibrillators used worldwide in health care facilities and public places may malfunction during attempts to rescue people in sudden cardiac arrest, the U.S. Food and Drug Administration (FDA) warned this week.

The Society for Cardiovascular Angiography and Interventions’ (SCAI) upcoming 33rd Annual Scientific Sessions promises the latest news in interventional cardiology from leading experts in the field. The event will take place May 5-8 in San Diego.

April 27, 2010 – The U.S. Food and Drug Administration (FDA) today announced it is changing the way it operates its medical device advisory panels, effective May 1.

April 27, 2010 – The U.S. Food and Drug Administration (FDA) this week cleared a large field-of-view, general-purpose portable nuclear imaging system.

April 27, 2010 – A popular statin gained a new indication today in the European Union for prevention of major cardiovascular events in patients who are at high risk of having a first cardiovascular event.

April 27, 2010 – New data show improved outcomes, better survival rates and lower costs with the use of continuous flow mechanical circulatory support devices in patients awaiting heart transplants. Research was presented last week during symposia at the International Society for Heart and Lung Transplantation (ISHLT) 30th Annual Meeting and Scientific Session in Chicago.

April 27, 2010 – New findings confirm atrial fibrillation (AF) is independently associated with the risk of all forms of dementia, including Alzheimer’s and other senile and vascular dementia types.

April 26, 2010 – A spatio-temporal evaluation of electrocardiogram (ECG) data may help with better identification of heart attacks in patients presenting with chest pain. Current methods are often not sufficient and heart damage can be present even if ECG and blood test results are unremarkable.

April 26, 2010 – The American College of Cardiology (ACC) today said it officially signed on to the Code for Interactions with Companies released by the Council of Medical Specialty Societies (CMSS).

April 22, 2010 — An improved formulation of epoprostenol for the treatment of primary pulmonary arterial hypertension (PAH) and pulmonary hypertension is now commercially available.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now